Anti-Human LAG-3 Recombinant Antibody (LAG-525), PerCP (HB613147)

Name: Anti-Human LAG-3 Recombinant Antibody (LAG-525), PerCP
Brand: abinScience
SKU: HB613147
Price: 268 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

50T
100T

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HB613147
Реактивность видов	Human
Применения	FCM
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG4, kappa
ID клона	LAG-525
Конъюгация	PerCP
Цель	CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3
Уровень эндотоксинов	Please contact with the lab for this information.
Чистота	>90% as determined by SDS-PAGE.
Связанные продукты	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4), PerCP
Номер доступа	P18627
Форма	Liquid
Буфер хранения	0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Store at 4°C for 12 months. Protect from light. Do not freeze.
Фон	Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag). 1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648 2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082 3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750 4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185 5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966 6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841 7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469 8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152 10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708
Примечание	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.